History of Antibiotics. From Salvarsan to Cephalosporins

REFERENCES

• Wallace WC, Cinat ME, Nastanski F, New epidemiology for postoperative nosocomial infections. Am Surg 2000;66:874–878.
   PubMed Web of Science ®Google Scholar
• Jones HW. Report of a series of cases of syphilis treated by Ehrlich's arsenobenzol at the Walter Reed General Hospital, District of Columbia. Boston Med Surg J 1911;164:381–383.
   Google Scholar
• Riethmiller S. From Atoxyl to Salvarsan: searching for the magic bullet. Chemotherapy 2005;51:234–242.
   PubMed Web of Science ®Google Scholar
• Thorburn AL. Paul Ehrlich: pioneer of chemotherapy and cure by arsenic (1854–1915). Br J Vener Dis. 1983 Dec;59(6):404–405.
   PubMedGoogle Scholar
• Schwartz RS. Paul Ehrlich's magic bullets. N Engl J Med 2004;350:1079–1080.
   PubMed Web of Science ®Google Scholar
• Iyer HV. History revisited-Prontosil red. N J Emerg Med. 2008 Aug;35(2):209–10.
   PubMed Web of Science ®Google Scholar
• Domagk G. Further progress in chemotherapy of bacterial infections. Nobel Lecture, December 12 194.
   Google Scholar
• Raju TN. The Nobel chronicles. 1939: Gerhard Domagk (1895–1964). Lancet 1999 Feb 20;353(9153):681.
   PubMed Web of Science ®Google Scholar
• Laub GR. Discovery of the sulfa drugs. South Med J 1986 Jun;79(6):782.
   PubMed Web of Science ®Google Scholar
• Medicine: Prontosil. TIME Magazine, December 28, 1936.
   Google Scholar
• Kalkut G. Sulfonamides and trimethoprim. Cancer Invest 1998;16(8):612–5.
   PubMed Web of Science ®Google Scholar
• Peabody JW, Seabury JH. Actinomycosis and nocardiosis. A review of basic differences in therapy. Am J Med 1960 Jan;28:99–115.
   PubMed Web of Science ®Google Scholar
• Arnold JH. Sulfamethoxazole in the treatment of persistent urological infections. Clin Med (Northfield Il). 1964 Mar;71:522–526.
   Google Scholar
• Jackson JM, Pelle M. Topical rosacea therapy: the importance of vehicles for efficacy, tolerability and compliance. J Drugs Dermatol 2011 Jun;10(6):627–33.
   PubMed Web of Science ®Google Scholar
• Lohr JA, Austin RD, Grossman M, Comparison of three topical antimicrobials for acute bacterial conjunctivitis. Pediatr Infect Dis J 1988 Sep;7(9):626–629.
   PubMed Web of Science ®Google Scholar
• Pearson RD, Hewlett EL. Use of pyrimethamine-sulfadoxine (Fansidar) in prophylaxis against chloroquine-resistant Plasmodium falciparum and Pneumocystis carinii. Ann Intern Med 1987 May;106(5):714–718.
   PubMed Web of Science ®Google Scholar
• White NJ. The treatment of malaria. N Engl J Med 1996 Sep 12;335(11):800–806.
   PubMed Web of Science ®Google Scholar
• Gleckman R, Blagg N, Joubert DW. Trimethoprim: mechanisms of action, antimicrobial activity, bacterial resistance, pharmacokinetics, adverse reactions, and therapeutic indications. Pharmacotherapy 1981 Jul-Aug;1(1):14–20.
   PubMed Web of Science ®Google Scholar
• Moran GJ, Krishnadasan A, Gorwitz RJ, Emergency ID Net Study Group. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med 2006 Aug 17;355(7):666–674.
   PubMed Web of Science ®Google Scholar
• Zhanel GG, Karlowsky JA, Harding GK, A Canadian national surveillance study of urinary tract isolates from outpatients: comparison of the activities of trimethoprim-sulfamethoxazole, ampicillin, mecillinam, nitrofurantoin, and ciprofloxacin. The Canadian Urinary Isolate Study Group. Antimicrob Agents Chemother 2000 Apr;44(4):1089–1092.
   PubMed Web of Science ®Google Scholar
• Pelton SI, Shurin PA, Klein JO, Quantitative inhibition of Haemophilus influenzae by trimethoprim/sulfamethoxazole. Antimicrob Agents Chemother 1977 Dec;12(6):649–654.
   PubMed Web of Science ®Google Scholar
• Green H, Paul M, Vidal L, Prophylaxis of Pneumocystis pneumonia in immunocompromised non-HIV-infected patients: systematic review and meta-analysis of randomized controlled trials. Mayo Clin Proc 2007 Sep;82(9):1052–1059.
   PubMed Web of Science ®Google Scholar
• DiRienzo AG, van Der Horst C, Finkelstein DM, Efficacy of trimethoprim-sulfamethoxazole for the prevention of bacterial infections in a randomized prophylaxis trial of patients with advanced HIV infection. AIDS Res Hum Retroviruses 2002 Jan 20;18(2):89–94.
   PubMed Web of Science ®Google Scholar
• Kärpänoja P, Nyberg ST, Bergman M, Finnish Study Group for Antimicrobial Resistance (FiRe Network). Connection between trimethoprim-sulfamethoxazole use and resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. Antimicrob Agents Chemother 2008 Jul;52(7):2480–2485.
   PubMed Web of Science ®Google Scholar
• Huovinen P. Resistance to trimethoprim-sulfamethoxazole. Clin Infect Dis 2001 Jun 1;32(11):1608–1614.
   PubMed Web of Science ®Google Scholar
• R Hare. New light on the history of penicillin. Medical History 1982;26:1–24.
   PubMed Web of Science ®Google Scholar
• Fleming A. On a remarkable bacteriolytic element found in tissues and secretions. Proc R Soc London (series B) 1921-22;98:306–317.
   Google Scholar
• Fleming A. On the antibacterial action of cultures of a penicillium, with special reference to their use in the isolation of B. influenzae. 1929. Bull World Health Organ 2001;79(8):780–790.
   PubMed Web of Science ®Google Scholar
• Hare R. The Birth of Penicillin. London: Allen&Unwin; 1970.
   Google Scholar
• E Chain, HW Florey, AD Gardner, Penicillin as a chemotherapeutic agent. Lancet 1940; ii:226–228.
   Google Scholar
• Abraham EP, Chain E, Fletcher CM, Further observations on penicillin. 1941. Eur J Clin Pharmacol 1992;42(1):3–9.
   PubMedGoogle Scholar
• Florey ME, Adelaide MB, Florey HW, General and local administration of penicillin. Lancet 1943;241:387–397.
   Google Scholar
• Grossman C, The first use of penicillin in the United States. Ann Intern Med July 15, 2008;149:135–136.
   PubMed Web of Science ®Google Scholar
• Maiti SN, Phillips OA, Micetich RG, Beta-lactamase inhibitors: agents to overcome bacterial resistance. Curr Med Chem 1998;5(6):441–456.
   PubMed Web of Science ®Google Scholar
• Rolinson GN. 6-APA and the development of the beta-lactam antibiotics. J. Antimicrob. Chemother 1979;5:7–14.
   PubMed Web of Science ®Google Scholar
• Wright AJ. The penicillins. Mayo Clin Proc 1999 Mar;74(3):290–307.
   PubMed Web of Science ®Google Scholar
• Tomasz A. Antibiotic resistance in Streptococcus pneumoniae. Clin Infect Dis 1997 Jan;24 (suppl 1)S85–S88.
   PubMed Web of Science ®Google Scholar
• Mulligan ME, Murray-Leisure KA, RIbner BS, Methicillin-resistant Staphylococcus aureus: a consensus review of the microbiology, pathogenesis, and epidemiology with implications for prevention and management. Am J Med 1993 Mar;94(3):313–328.
   PubMed Web of Science ®Google Scholar
• Gold HS, Moellering RC. Antimicrobial-drug resistance. N Engl J Med 1996 Nov 7;335(19):1445–1453.
   PubMed Web of Science ®Google Scholar
• Abraham EP, Chain E. An enzyme from bacteria able to destroy penicillin. 1940. Rev Infect Dis 1988 Jul-Aug;10(4):677–678.
   PubMedGoogle Scholar
• Bush LM, Johnson CC. Ureidopenicillins and beta-lactam/beta-lactamase inhibitor combinations. Infect Dis Clin North Am 2000 Jun;14(2):409–433, ix.
   PubMed Web of Science ®Google Scholar
• Finland M, Frank PF, Wilcox C. In vitro susceptibility of pathogenic staphylococci to seven antibiotics. Am J Clin Pathol 1950,20;325–334.
   PubMed Web of Science ®Google Scholar
• Lowy FD. Staphylococcus aureus infections. N Engl J Med 1998Aug 20;339(8):520–532.
   PubMed Web of Science ®Google Scholar
• Whitney CG, Farley MM, Hadler J ,et al. Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States. N Engl J Med 2000 Dec 28;343(26):1917–1924.
   PubMed Web of Science ®Google Scholar
• Eickhoff TC, Finland M. Changing susceptibility of meningococci to antimicrobial agents. N Engl J Med 1965;272:395–398.
   PubMed Web of Science ®Google Scholar
• Herman DJ, Gerding DN. Antimicrobial resistance among enterococci. Antimicrob Agents Chemother 1991 Jan;35(1):1–4.
   PubMed Web of Science ®Google Scholar
• Betriu C, Sanchez A, Gomez M, Antibiotic susceptibility of group A streptococci: a 6-year follow-up study. Antimicrob Agents Chemother 1993 Aug;37(8):1717–1719.
   PubMed Web of Science ®Google Scholar
• Schuchat A, Wenger JD. Epidemiology of group B streptococcal disease. Risk factors, prevention strategies, and vaccine development. Epidemiol Rev 1994;16(2):374–402.
   PubMed Web of Science ®Google Scholar
• Carroll KC, Monroe P, Cohen S, Susceptibility of beta-hemolytic streptococci to nine antimicrobial agents among four medical centers in Salt Lake City, Utah, USA. Diagn Microbiol Infect Dis 1997 Apr;27(4):123–128.
   PubMed Web of Science ®Google Scholar
• Lorber B. Listeriosis. Clin Infect Dis 1997 Jan;24(1):1–9.
   PubMed Web of Science ®Google Scholar
• Denny FW, Wannamaker LW, Brink WR, Prevention of rheumatic fever. Treatment of the preceding streptococcic infection. JAMA 1985 Jul 26;254(4):534–537.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Rheumatic Fever and Rheumatic Heart Disease. Geneva, Switzerland: World Health Organization; 2004.
   Google Scholar
• Mahoney JF, Arnold RC, Sterner BL, Penicillin treatment of early syphilis. JAMA 1944;126(2):63–67.
   Google Scholar
• Moore JE, Mahoney JF, Schwartz W, The treatment of early syphilis with penicillin. JAMA 1944;126(2):67–73.
   Google Scholar
• Miyake CY, Gauvreau K, Tani LY, Characteristics of children discharged from hospitals in the United States in 2000 with the diagnosis of acute rheumatic fever. Pediatrics 2007 Sep;120(3):503–508.
   PubMed Web of Science ®Google Scholar
• Del Mar CB, Glasziou PP, Spinks AB. Antibiotics for sore throat. Cochrane Database Syst Rev 2006 Oct 18;(4):CD000023.
   Google Scholar
• Centers for Disease Control and Prevention. Sexually Transmitted Disease Surveillance, 2006. Atlanta, GA: US Dept of Health and Human Services; November 2007.
   Google Scholar
• Armstrong GL, Conn LA, Pinner RW. Trends in infectious disease mortality in the United States during the 20th century. JAMA 1999;281(1):61–66.
   PubMed Web of Science ®Google Scholar
• Donowitz GR, Mandell GL. Beta-lactam antibiotics, N Engl J Med. 1988;318(7): 419-26 and 318(8):490–500.
   PubMed Web of Science ®Google Scholar
• Rolison GN, Stevens S, Batchelor FR. Bacteriological studies on a new penicillin-BRL. 1241. Lancet 1960 Sep 10;2(7150):564–567.
   PubMedGoogle Scholar
• Simon HJ, Rantz LA. The newer penicillins. I. Bacteriological and clinical pharmacological investigations with methicillin and oxacillin. Ann Intern Med 1962 Sep;57:335–343.
   PubMed Web of Science ®Google Scholar
• Barber M. Methicillin-resistant staphylococci. J Clin Pathol 1961;14:385–393.
   PubMed Web of Science ®Google Scholar
• Jarvis WR, Schlosser J, Chinn RY, National prevalence of methicillin-resistant Staphylococcus aureus in inpatients in US health care facilities, 2006. Am J Infect Control 2007;35:631–637.
   PubMed Web of Science ®Google Scholar
• Rolinson GN, Stevens S. Microbiological studies on a new broad spectrum penicillin ‘Penbritin’. Br Med J 1961 Jul 22;2(5246):191–196.
   PubMedGoogle Scholar
• Brogden RN, Speight TM, Avery GS. Amoxycillin: a review of its antibacterial and pharmacokinetic properties and therapeutic use. Drugs 1975; 9:88–140.
   PubMed Web of Science ®Google Scholar
• Dowell SF, Butler JC, Giebink GS, Acute otitis media: management and surveillance in an era of pneumococcal resistance—a report from the Drug-Resistant Streptococcal pneumoniae Therapeutic Working Group. Pediatr Infect Dis J 1999;18:1–9.
   PubMed Web of Science ®Google Scholar
• Shvartzman P, Tabenkin H, Rosentzqaig A, Treatment of streptococcal pharyngitis with amoxycillin once a day. BMJ 1993; 306:1170–1172.
   PubMed Web of Science ®Google Scholar
• Ronald AR, Jagdis FA, Harding GK, Amoxicillin therapy of acute urinary infections in adults. Antimicrob Agents Chemother 1977;11:780–784.
   PubMed Web of Science ®Google Scholar
• George LL, Borody TJ, Andrews P, Cure of duodenal ulcer after eradication of H. pylori. Med J Aust 1990;153:145–149.
   PubMed Web of Science ®Google Scholar
• Huang JQ, Sridhar S, Chen Y, Meta-analysis of the relationship between Helicobacter pylori seropositivity and gastric cancer. Gastroenterology 1998 Jun;114(6):1169–1179.
   PubMed Web of Science ®Google Scholar
• D'Elios MM, Amedei A, Manghetti M, Impaired T-cell regulation of B-cell growth in Helicobacter pylori–related gastric low-grade MALT lymphoma. Gastroenterology 1999 Nov;117(5):1105–1112.
   PubMed Web of Science ®Google Scholar
• Alary M, Joly JR, Moutquin JM, Randomised comparison of amoxycillin and erythromycin in treatment of genital chlamydial infection in pregnancy. Lancet 1994; 344:1461–1465.
   PubMedGoogle Scholar
• Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines 2002. MMWR Morb Mortal Wkly Rep 2002;51(No. RR-6):1–78.
   Google Scholar
• Deeks SL, Palacio R, Ruvinsky R, Risk factors and course of illness among children with invasive penicillin-resistant Streptococcus pneumoniae. The Streptococcus pneumoniae Working Group. Pediatrics 1999;103(2):409.
   PubMed Web of Science ®Google Scholar
• Sanders WE, Sanders CC. Piperacillin/tazobactam: a critical review of the evolving clinical literature. Clin Infect Dis 1996 Jan;22(1):107–123.
   PubMed Web of Science ®Google Scholar
• Hurwitz C. Mechanism of action of streptomycin. Antimicrob Agents Chemother 1963;161:371–386.
   PubMedGoogle Scholar
• Comroe JH. Pay dirt: the story of streptomycin. Part I. From Waksman to Waksman. Am Rev Respir Dis 1978 Apr;117(4):773–781.
   PubMedGoogle Scholar
• Pfuetze KH, Pyle MM, HInshaw HC, The first clinical trial of streptomycin in human tuberculosis. Am Rev Tuberc 1955 May;71(5):752–754.
   PubMedGoogle Scholar
• Kaplan D, Koch W. Weighted temperature elevation: a measure of skin reactivity. Br J Dermatol 1965 Dec;77(12):650–265.
   PubMed Web of Science ®Google Scholar
• Waddington K. To stamp out “so terrible a malady”: bovine tuberculosis and tuberculin testing in Britain, 1890-1939. Med Hist 2004 Jan;48(1):29–48.
   PubMed Web of Science ®Google Scholar
• Strandberg O. Treatment of Rhino-laryngological tuberculosis by Finsen light baths, and results. Proc R Soc Med 1924;17(Gen Rep):25–30.
   PubMedGoogle Scholar
• McCarthy OR. The key to the sanatoria. J R Soc Med 2001 Aug;94(8):413–417.
   PubMed Web of Science ®Google Scholar
• Waksman SA. The actinomyces and their antibiotics. Adv Appl Microbiol 1963;5:235–315.
   PubMedGoogle Scholar
• Schatz A, Waksman SA. Effect of streptomycin and other antibiotic substances upon Mycobacterium tuberculosis and related organisms. Proc Soc Exp Biol Med Nov 1944; 57:244–248.
   Google Scholar
• Smith DG, Waksman SA. Tuberculostatic and tuberculocidal properties of streptomycin. J Bacteriol 1947 Aug;54(2):253–261.
   PubMed Web of Science ®Google Scholar
• Schatz A, Bugie E, Waksman SA. Streptomycin, a substance exhibiting antibiotic activity against gram-positive and gram-negative bacteria. 1944. Clin Orthop Relat Res 2005 Aug;(437):3–6.
   PubMed Web of Science ®Google Scholar
• Dickinson L. Effect of streptomycin on experimental tuberculosis in guinea-pigs. Br J Pharmacol Chemother 1947 Mar;2(1):23–26.
   PubMed Web of Science ®Google Scholar
• Hinshaw HC, Feldman WH. Streptomycin: a summary of clinical and experimental observations. J Pediatr 1946 Mar;28:269–274.
   PubMed Web of Science ®Google Scholar
• Hinshaw HC, Feldman WH. The in vivo sensitivity to streptomycin of recently isolated strains of human tubercle bacilli. Am J Pathol 1946 May;22:640.
   PubMed Web of Science ®Google Scholar
• Williston EH, Youman GP. Streptomycin resistant strains of tubercle bacilli: production of streptomycin resistance in vitro. Am Rev Tuberc 1947 Jun;55(6):536–539.
   PubMedGoogle Scholar
• Feldman WH, Karlson AG, Hinshaw HC. Streptomycin-resistant tubercle bacilli: effect of resistance on therapeutic results. Am J Pathol 1947 Sep;23(5):874.
   PubMed Web of Science ®Google Scholar
• Medical Research Council. Isoniazid in combination with streptomycin or with P.A.S. in the treatment of pulmonary tuberculosis; fifth report to the Medical Research Council by their Tuberculosis Chemotherapy Trials Committee. Br Med J 1953 Nov 7;2(4844):1005–1014.
   PubMedGoogle Scholar
• Fox W, Sutherland I, Daniels M. A five-year assessment of patients in a controlled trial of streptomycin in pulmonary tuberculosis; report to the Tuberculosis Chemotherapy Trials Committee of the Medical Research Council. Q J Med 1954 Jul;23(91):347–366.
   PubMedGoogle Scholar
• Lehman J. Para-aminosalicylic acid in the treatment of tuberculosis. Lancet 1946 Jan 5;1(6384):15.
   PubMedGoogle Scholar
• Lehman J. On the effect of isomers of para-aminosalicylic acid and related substances on the tuberculostatic effect of PAS. Experientia 1949 Sep 15;5(9):365–367.
   PubMedGoogle Scholar
• Mc Dermott W, Muschenheim C, Clark C, Isonicotinic acid hydrazide in tuberculosis in man. Trans Assoc Am Physicians 1952;65:191–202.
   PubMedGoogle Scholar
• Mitchison DA. Role of individual drugs in the chemotherapy of tuberculosis. Int J Tuberc Lung Dis 2000 Sep;4(9):796–806.
   PubMed Web of Science ®Google Scholar
• Simon HJ. Streptomycin, kanamycin, neomycin and paromomycin. Pediatr Clin North Am 1968 Feb;15(1):73–83.
   PubMed Web of Science ®Google Scholar
• American Thoracic Society/Centers for Disease Control and Prevention/Infectious Disease Society of America. Treatment of tuberculosis. Am J Respir Crit Care Med 2003;167:603–662.
   PubMed Web of Science ®Google Scholar
• American Thoracic Society. Diagnosis and treatment of disease caused by nontuberculosis mycobacteria. Am J Respir Crit Care Med 1997;156:1–25.
   PubMed Web of Science ®Google Scholar
• Finken M, Kirschner P, Meier A, Molecular basis of streptomycin resistance in Mycobacterium tuberculosis: alterations of the ribosomal protein S12 gene and point mutations within a functional 16S ribosomal RNA pseudoknot. Mol Microbiol 1993 Sep;9(6):1239–1246.
   PubMed Web of Science ®Google Scholar
• Bayram Y, Korkoca H, Aypak C, Antimicrobial susceptibilities of Brucella isolates from various clinical specimens. I nt J Med Sci 2011 Mar 3;8(3):198–202.
   Google Scholar
• Enderlin G, Morales L, Jacobs RF, Streptomycin and alternative agents for the treatment of tularemia: review of the literature. Clin Infect Dis 1994 Jul;19(1):42–47.
   PubMed Web of Science ®Google Scholar
• Richens J. The diagnosis and treatment of donovanosis (granuloma inguinale). Genitourin Med 1991 Dec;67(6):441–452.
   PubMedGoogle Scholar
• Thornsberry C, Baker CN, Facklam RR. Antibiotic susceptibility of Streptococcus bovis and other group D streptococci causing endocarditis. Antimicrob Agents Chemother 1974 Mar;5(3):228–233.
   PubMed Web of Science ®Google Scholar
• Tompsett R, Berman W. Enterococcal endocarditis: duration and mode of treatment. Trans Am Clin Climatol Assoc 1978;89:49–57.
   PubMedGoogle Scholar
• Chow JW. Aminoglycoside resistance in enterococci. Clin Infect Dis 2000 Aug;31(2):586–589.
   PubMed Web of Science ®Google Scholar
• Darville T, Yamauchi T. The cephalosporin antibiotics. Pediatrics Rev Jan 2011;15 (2): 54.
   Google Scholar
• Bo G. Giuseppe Brotzu and the discovery of cephalosporins. Clin Microbiol Infect 2000;6 suppl 3:6–9.
   PubMed Web of Science ®Google Scholar
• Burton HS, Abraham EP. Isolation of antibiotics from a species of Cephalosporium. Cephalosporins P1, P2, P3, P4 and P5. Biochem J 1951;50:168–174.
   PubMed Web of Science ®Google Scholar
• Newton GGF, Abraham EP. The degradation, structure and some derivatives of cephalosporin N. Biochem J 1951;58:103–111.
   Google Scholar
• Hamilton-Miller JMT. Sir Edward Abraham's contribution to the development of the cephalosporins: a reassessment. Int J Antimicrob Agents 2000;15(3):179–184.
   PubMed Web of Science ®Google Scholar
• Abraham EP, Newton GGF. The structure of cephalosporin C. Biochem J 1961; 79:377–393.
   PubMed Web of Science ®Google Scholar
• Abraham EP, Newton GGF. Experiments on degradation of cephalosporin C. Biochem J 1956;62:658–665.
   PubMed Web of Science ®Google Scholar
• Hale CW, Newton GGF, Abraham EP. Derivatives of cephalosporin C formed with certain heterocyclic tertiary bases. Biochem J. 1961;79:403–408.
   PubMed Web of Science ®Google Scholar
• Morin RB, Jackson BG, Muller RA, Chemistry of cephalosporin antibiotics. II. Chemical correlation of penicillin and cephalosporin antibiotics. J Am Chem Soc 1963; 785:1896–1897.
   Google Scholar
• Loder B, Newton GGF, Abraham EP. The cephalosporin C nucleus (7-amino-cephalosporanic acid) and some of its derivatives, Biochem J 1961;79:408–416.
   PubMed Web of Science ®Google Scholar
• Wick WE. Cephalexin, a new orally absorbed cephalosporin antibiotic. Appl Microbiol 1967;15:765–769.
   PubMedGoogle Scholar
• Donowitz GR, Mandell GL. Drug therapy: beta-lactam antibiotics. N Engl J Med 1988; 318(7):419–426.
   PubMed Web of Science ®Google Scholar
• Hodges GR, Saslaw S. Experiences with cefazolin: a new cephalosporin antibiotic. Am J Med Sci 1973 Jan;265(1):23–32.
   PubMed Web of Science ®Google Scholar
• Gurwith M, Albritton W, Lank B, Prospective comparison of cefoxitin and cefazolin in infections caused by aerobic bacteria. Antimicrob Agents Chemother 1978 Feb;13(2):255–260.
   PubMed Web of Science ®Google Scholar
• Finkelstein R, Rabino G, Mashiah T, Vancomycin versus cefazolin prophylaxis for cardiac surgery in the setting of a high prevalence of methicillin-resistant staphylococcal infections. J Thorac Cardiovasc Surg 2002 Feb;123(2):326–332.
   PubMed Web of Science ®Google Scholar
• Fung HB, Chang JY, Kuczynski S. A practical guide to the treatment of complicated skin and soft tissue infections. Drugs 2003;63(14):1459–1480.
   PubMed Web of Science ®Google Scholar
• Derry JE. Evaluation of cefaclor. Am J Hosp Pharm 1981 Jan;38(1):54–58.
   PubMedGoogle Scholar
• Law MR, Holt HA, Reeves DS, Cefaclor and amoxycillin in the treatment of infective exacerbations of chronic bronchitis. J Antimicrob Chemother 1983 Jan;11(1):83–88.
   PubMed Web of Science ®Google Scholar
• Drehobl M, Bianchi P, Keyserling CH, Comparison of cefdinir and cefaclor in treatment of community-acquired pneumonia. Antimicrob Agents Chemother 1997 Jul;41(7):1579–1583.
   PubMed Web of Science ®Google Scholar
• Spagna VA, Perkins RL, Prior RB. Successful treatment with cefaclor of gonococcal urethritis in men. Sex Transm Dis 1979 Jul-Sep;6(3):211–213.
   PubMed Web of Science ®Google Scholar
• Schaad UB, Suter S, Gianella-Borradori A, A comparison of ceftriaxone and cefuroxime for the treatment of bacterial meningitis in children. N Engl J Med 1990 Jan 18;322(3):141–147.
   PubMed Web of Science ®Google Scholar
• Beam TR. Cephalosporins in adult meningitis. Bull N Y Acad Med 1984 May;60(4):380–393.
   PubMedGoogle Scholar
• Farber B, Moellering RC. The third generation cephalosporins. Bull N Y Acad Med 1982 Nov;58(8): 696–710.
   PubMedGoogle Scholar
• Giamarellou H. Fourth generation cephalosporins in the antimicrobial chemotherapy of surgical infections. J Chemother 1999 Dec;11(6):486–493.
   PubMed Web of Science ®Google Scholar
• Wilson WR. The role of fourth-generation cephalosporins in the treatment of serious infectious diseases in hospitalized patients. Diagn Microbiol Infect Dis 1998 Jul;31(3):473–477.
   PubMed Web of Science ®Google Scholar
• Tapsall JW. Neisseria gonorrhoeae and emerging resistance to extended spectrum cephalosporins. Curr Opin Infect Dis 2009 Feb;22(1):87–91.
   PubMed Web of Science ®Google Scholar
• McNabb J, Quintiliani R, Nightingale CH, Comparison of the bactericidal activity of trovafloxacin and ciprofloxacin, alone and in combination with cefepime, against Pseudomonas aeruginosa. Chemotherapy 2000 Nov-Dec;46(6):383–389.
   PubMed Web of Science ®Google Scholar
• Paterson DL, Bonomo RA. Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev 2005 Oct;18(4):657–686.
   PubMed Web of Science ®Google Scholar
• Endimiani A, Perez F, Bonomo RA. Cefepime: a reappraisal in an era of increasing antimicrobial resistance. Expert Rev Anti Infect Ther 2008 Dec;6(6):805–824.
   PubMed Web of Science ®Google Scholar
• Deal EN, Micek ST, Reichley RM, Effects of an alternative cefepime dosing strategy in pulmonary and bloodstream infections caused by Enterobacter spp, Citrobacter freundii, and Pseudomonas aeruginosa: a single-center, open-label, prospective, observational study. Clin Ther 2009 Feb;31(2):299–310.
   PubMed Web of Science ®Google Scholar
• Fish DN, Choi MK, Jung R. Synergic activity of cephalosporins plus fluoroquinolones against Pseudomonas aeruginosa with resistance to one or both drugs. J Antimicrob Chemother 2002 Dec;50(6):1045–1049.
   PubMed Web of Science ®Google Scholar
• Zhanel GG, Lam A, Schweizer F, Ceftobiprole: a review of a broad-spectrum and anti-MRSA cephalosporin. Am J Clin Dermatol 2008;9(4):245–254.
   PubMed Web of Science ®Google Scholar